Market Intelligence, Clinical Progress, and High-Purity Reagents for Multidrug Resistance and Safety Profiling.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for MRP2/ABCC2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MRP2/ABCC2 Intracellular Domain (NBD) Mutant / Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View MRP2 Products |
| Gene Delivery | MRP2/ABCC2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Native conformation preservation. |
View MRP2 Products |
| Benchmark Ab | Anti-MRP2 Recombinant Antibody Recombinant positive control for expression and localization assays. |
View MRP2 Products |
| Validator | MRP2/ABCC2 siRNA Set For knockdown verification and specificity profiling. |
View MRP2 Products |
| Related Target A | ABCB1 (P-gp) Synergistic multidrug resistance efflux pump co-expressed in barrier tissues. |
View ABCB1 Products |
| Related Target B | ABCG2 (BCRP) Critical co-transporter in blood-brain barrier and intestinal drug efflux. |
View ABCG2 Products |
| Related Target C | ABCC1 (MRP1) Subfamily homolog critical for off-target selectivity screening. |
View ABCC1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformation preservation of multi-pass membrane protein | Lentivirus for stable cell line expression (native 17-TMD conformation) |
| Subfamily cross-reactivity (MRP1/MRP3/MRP4) | Homolog panel proteins strictly verified by sequence alignment and mass spec |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live MRP2/ABCC2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The landscape for MRP2 (ABCC2) therapeutics and diagnostics is expanding rapidly. As a key ATP-binding cassette (ABC) transporter, MRP2 is heavily implicated in multidrug resistance (MDR) in solid tumors and plays a critical role in Drug-Induced Liver Injury (DILI) and hyperbilirubinemia (Dubin-Johnson Syndrome). The race for MRP2 modulators is intensifying, with major players shifting focus from traditional non-selective ABC blockers to highly selective small molecule molecules and RNA-targeting therapeutics. As first-generation therapies reach the clinic, the next wave of R&D is targeting precise interaction interfaces and safety-profiling assays to avoid systemic toxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Eisai, Merck, Solvo Biotechnology | Chemotherapy-resistant Solid Tumors | Efflux Assay (Need Lentivirus for Stable Cell Lines) |
| RNA Therapeutics (siRNA/ASO) | Alnylam, Ionis Pharmaceuticals | Dubin-Johnson Syndrome, Liver Diseases | Target Knockdown Validation (Need Validated siRNA Set) |
| ADME/Tox Screening Panels | Eurofins, Charles River, Cyprotex | Drug-Induced Liver Injury (DILI) | Vesicular Transport Assay (Need Recombinant Intracellular Domain) |